WO2023221240A1 - Composition et procédé pour générer un baculovirus recombiné dans une cellule d'insecte, et utilisation - Google Patents

Composition et procédé pour générer un baculovirus recombiné dans une cellule d'insecte, et utilisation Download PDF

Info

Publication number
WO2023221240A1
WO2023221240A1 PCT/CN2022/101538 CN2022101538W WO2023221240A1 WO 2023221240 A1 WO2023221240 A1 WO 2023221240A1 CN 2022101538 W CN2022101538 W CN 2022101538W WO 2023221240 A1 WO2023221240 A1 WO 2023221240A1
Authority
WO
WIPO (PCT)
Prior art keywords
sequence
baculovirus
recombinant
expression cassette
gene expression
Prior art date
Application number
PCT/CN2022/101538
Other languages
English (en)
Chinese (zh)
Inventor
肖何
何晓斌
黄刚
胡颖
Original Assignee
睿征医药科技(武汉)有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 睿征医药科技(武汉)有限公司 filed Critical 睿征医药科技(武汉)有限公司
Publication of WO2023221240A1 publication Critical patent/WO2023221240A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0601—Invertebrate cells or tissues, e.g. insect cells; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention belongs to the field of genetic engineering technology, and more specifically, relates to a composition, method and application for producing recombinant baculovirus in insect cells.
  • Baculovirus is a type of enveloped circular double-stranded DNA virus. The most studied baculovirus strain at present is Autographa californica multinuclear polyhedrosis virus (MNPV), referred to as AcMNPV.
  • MNPV Autographa californica multinuclear polyhedrosis virus
  • BEVS Baculovirus expression system
  • BEVS Baculovirus expression system
  • Kitts et al. proposed the BacPAK baculovirus expression system, which inserts the lacZ gene into the polyhedrosis virus locus and constructs a Bsu36I enzyme-containing Bsu36I enzyme cleavage site by introducing a Bsu36I restriction site into the orf1629 and orf603 gene loci.
  • Replication-deficient viruses that are linearized after cleavage. Due to the deletion of the essential gene orf1629, the linearized viruses cannot produce viruses with infectious activity even if they are self-ligated.
  • the recombinant DNA transfer vector and the linearized virus will be co-transfected into the host. In insect cells, recombinant baculovirus is obtained after homologous recombination.
  • the Bsu36I enzyme cannot cleave 100% of the viral DNA to linearize it, the recombinant virus still needs to undergo plaque screening, which is time-consuming and labor-intensive.
  • Zhao et al. proposed the flash-BAC system.
  • This system introduced the mini-F replicon into the AcMNPV genome and at the same time inactivated the essential gene orf1629.
  • the baculovirus in which the essential gene orf1629 was inactivated was unable to produce infection. Active virus unless homologous recombination occurs with the rescue recombinant DNA transfer vector.
  • This system combines the advantages of BacPAK and Bac-to-Bac and requires only one step of recombination in host insect cells to obtain recombinant baculovirus without screening.
  • orf1629 is a trans-element protein related to replication
  • viral DNA that has undergone homologous recombination will provide the function of orf1629, and since viral DNA that has not undergone homologous recombination will also be packaged, resulting in the final Recombinant baculovirus is impure.
  • the purpose of the present invention is to provide a composition, method and application for producing recombinant baculovirus in insect cells, aiming to solve the problem of using the flash-BAC system to produce recombinant baculovirus.
  • Viral DNA that has not undergone homologous recombination will also be packaged, and viral DNA that has undergone homologous recombination will provide the function of orf1629, leading to the problem of impurity of the recombinant baculovirus.
  • the present invention provides a composition for producing recombinant baculovirus in insect cells, comprising a packaging-defective baculovirus plasmid and a first rescue recombinant DNA
  • the packaging-defective baculovirus plasmid is deleted CNE sequence and/or NAE sequence in the baculovirus genome
  • the first rescue recombinant DNA includes a first insertion sequence and a first homology arm located on both sides of the first insertion sequence
  • the first insertion sequence includes A first functional fragment and a first complement sequence
  • the first complement sequence is at least one of the sequences deleted from the packaging-deficient baculovirus plasmid
  • the composition is capable of homologous recombination in insect cells. to produce recombinant baculovirus.
  • the first functional fragment is the cap gene expression cassette of AAV and the rep gene expression cassette of AAV.
  • the first insertion sequence includes the cap gene expression cassette, the first complement sequence and the rep gene expression cassette in order from 5' to 3'.
  • the first insertion sequence includes the rep gene expression cassette, the first complement sequence and the cap gene expression cassette in order from 5' to 3'.
  • the first complementing sequence is located between the cap gene expression cassette and the rep gene expression cassette, and its two ends are respectively close to the starting end of the cap gene expression cassette and the rep gene expression cassette. Starting end.
  • the packaging-deficient baculovirus plasmid is a recombinant bacmid containing an AAV ITR core expression element with a foreign gene.
  • the recombinant bacmid is obtained by Tn7 transposition mediated by a baculovirus transfer vector.
  • the first functional fragment is an AAV ITR core expression element carrying an exogenous gene.
  • the packaging-deficient baculovirus plasmid is a recombinant bacmid containing an AAV cap gene expression cassette and an AAV rep gene expression cassette.
  • the recombinant bacmid is obtained by Tn7 transposition mediated by a baculovirus transfer vector.
  • the first functional fragment is a reporter gene.
  • the first functional fragment is a nucleotide sequence encoding a therapeutic gene product.
  • the composition further comprises a second rescue recombinant DNA
  • the packaging-deficient baculovirus plasmid deletes the CNE sequence and the NAE sequence in the baculovirus genome
  • the second rescue recombinant DNA comprises a second insertion sequence and The second homology arms located on both sides of the second insertion sequence
  • the second insertion sequence includes a second complementation sequence
  • the first complementation sequence is a CNE sequence or an NAE sequence
  • the second complementation sequence It is the sequence different from the first complement sequence in the CNE sequence and the NAE sequence.
  • the first functional fragment is the cap gene expression cassette of AAV and the rep gene expression cassette of AAV
  • the second insertion sequence also includes a second functional fragment
  • the second functional fragment is a gene containing an exogenous gene.
  • AAV ITR core expression element is the first functional fragment.
  • compositions for preparing recombinant baculovirus and/or recombinant adeno-associated virus in insect cells are provided.
  • an insect cell comprising any of the above compositions.
  • a method for growing or producing recombinant baculovirus in vitro comprising co-transfecting insect cells with any of the above compositions and culturing the insect cells.
  • a method for growing or producing recombinant adeno-associated viruses in vitro comprising co-transfecting insect cells with any of the above compositions and culturing the insect cells.
  • the present invention improves on the basis of the flash-BAC system to construct a packaging-deficient baculovirus plasmid, which lacks the CNE sequence and/or NAE sequence in the baculovirus genome and cannot package the baculovirus normally unless rescued. Homologous recombination occurs in recombinant DNA. This system only requires one step of recombination in host insect cells to obtain recombinant baculovirus without screening; at the same time, the insertion sequence can be inserted into any locus of the baculovirus genome, and there is no restriction on the insertion site, and it can be inserted into the baculovirus genome as needed.
  • Figure 1 is a schematic diagram of the first homologous recombination expression box targeting CNE sequence constructed in Example 1 of the present invention.
  • Figure 2 is a schematic diagram of the second homologous recombination expression box targeting the NAE sequence constructed in Example 1 of the present invention.
  • Figure 3 is a schematic diagram of the third homologous recombination expression box targeting NAE sequence constructed in Example 1 of the present invention.
  • Figure 4 is a schematic diagram of the recombinant DNA fragment Ac96-CNE-GFP constructed in Example 2 of the present invention with the insertion site at orf96.
  • Figure 5 is a schematic diagram of the recombinant DNA fragment Ac96-NAE-mcherry with the insertion site at orf96 constructed in Example 2 of the present invention.
  • Figure 6 is a schematic diagram of the recombinant DNA fragment Ac96-Rep-CNE-Cap containing AAV Cap and Rep expression cassette constructed in Example 2 of the present invention.
  • Figure 7 is a schematic diagram of the recombinant DNA fragment Ac96-Rep-NAE-Cap containing AAV Cap and Rep expression cassette constructed in Example 2 of the present invention.
  • Figure 8 is a green fluorescent plaque diagram produced after co-transfection of insect host cells using defective baculovirus vector ⁇ CNE-Bac and recombinant DNA fragment Ac96-CNE-GFP in Example 3 of the present invention.
  • Figure 9 shows the effect of expressing green fluorescence after the recombinant baculovirus infects the cells after co-transfecting insect host cells with the defective baculovirus vector ⁇ CNE-Bac and the recombinant DNA fragment Ac96-CNE-GFP in Example 3 of the present invention. picture.
  • Figure 10 is a red fluorescent plaque diagram produced after co-transfection of insect host cells with defective baculovirus vector ⁇ NAE-Bac and recombinant DNA fragment Ac96-NAE-mcherry in Example 3 of the present invention.
  • Figure 11 shows the effect of the recombinant baculovirus expressing red fluorescence after infecting the cells after co-transfecting insect host cells with the defective baculovirus vector ⁇ NAE-Bac and the recombinant DNA fragment Ac96-NAE-mcherry in Example 3 of the present invention. picture.
  • Figures 12A-F are schematic diagrams of the recombinant DNA fragments constructed in Example 4 of the present invention with insertion sites at orf83, orf126 and orf152 respectively.
  • Figure 13 shows the results produced by co-transfecting insect host cells with the defective baculovirus vector ⁇ CNE-Bac and the recombinant DNA fragments Ac83-CNE-GFP, Ac126-CNE-GFP and Ac152-CNE-GFP in Example 4 of the present invention.
  • Figure 14 shows the results obtained after co-transfecting insect host cells with the defective baculovirus vector ⁇ CNE-Bac and the recombinant DNA fragments Ac83-CNE-GFP, Ac126-CNE-GFP and Ac152-CNE-GFP in Example 4 of the present invention.
  • Figure 15 shows the results produced by co-transfecting insect host cells with the defective baculovirus vector ⁇ NAE-Bac and the recombinant DNA fragments Ac83-NAE-mcherry, Ac126-NAE-mcherry and Ac152-NAE-mcherry in Example 4 of the present invention. Red fluorescent plaque diagram.
  • Figure 16 shows Example 4 of the present invention using defective baculovirus vector ⁇ NAE-Bac to co-transfect insect host cells with recombinant DNA fragments Ac83-NAE-mcherry, Ac126-NAE-mcherry and Ac152-NAE-mcherry. The effect of expressing red fluorescence after the recombinant baculovirus infects cells.
  • Figure 17 is a Western Blot detection of expression of VP capsid protein and Rep protein after co-transfection of insect host cells using defective baculovirus vector ⁇ CNE-Bac and recombinant DNA fragment Ac96-Rep-CNE-Cap in Example 5 of the present invention. picture.
  • Figure 18 is a Western Blot detection of expression of VP capsid protein and Rep protein after co-transfection of insect host cells using defective baculovirus vector ⁇ NAE-Bac and recombinant DNA fragment Ac96-Rep-NAE-Cap in Example 5 of the present invention. picture.
  • Figure 19 is a schematic diagram of the recombinant DNA fragment Ac83-ITR-NAE containing the AAV core expression element ITR-GOI constructed in Example 8 of the present invention.
  • Figure 20 is a silver staining detection picture of the purified recombinant AAV virus particles subjected to SDS-PAGE after the three recombinant baculoviruses were transfected into host cells in Example 9 of the present invention, all showing the three capsid proteins VP1/VP2/VP3. .
  • first and second are used for descriptive purposes only and cannot be understood as indicating or implying relative importance or implicitly indicating the quantity of indicated technical features. Therefore, features defined as “first” and “second” may explicitly or implicitly include at least one of these features.
  • plural means at least two, such as two, three, etc., unless otherwise expressly and specifically limited.
  • severeal means at least one, such as one, two, etc., unless otherwise expressly and specifically limited.
  • an expression cassette refers to a nucleic acid construct comprising coding and regulatory sequences operably linked when introduced into a host cell, resulting in the transcription and/or translation of RNA or polypeptide, respectively.
  • An expression cassette is understood to include a promoter allowing the initiation of transcription, the open reading frame of the gene of interest and a transcription terminator. Typically, the promoter sequence is placed upstream of the gene of interest at a distance compatible with expression control.
  • Cis-acting elements refer to specific DNA sequences connected in series with structural genes and are binding sites for transcription factors. They regulate the precise initiation and transcription efficiency of gene transcription by binding to transcription factors. Cis-acting elements include promoters, enhancers, regulatory sequences and inducible elements. Their role is to participate in the regulation of gene expression. They do not encode any protein themselves, but only provide an action site.
  • AAV is a single-stranded DNA virus with a simple genome structure and a full length of about 4.7kb. Its genome contains a rep gene expression cassette, a cap gene expression cassette and AAV inverted terminal repeats (ITR) located at both ends of the genome. These are the three elements necessary for packaging the AAV virus.
  • the Cap gene encodes a structural VP capsid protein, which contains three overlapping open reading frames, encoding three types of subunits: VP1, VP2, and VP3 respectively.
  • the Rep gene encodes four overlapping multifunctional proteins, Rep78, Rep68, Rep52 and Rep40, which are involved in AAV replication and integration.
  • ITR is a 125-nucleotide palindromic structure at both ends of the genome, which can form a self-complementary inverted T-shaped hairpin structure. It is a cis-acting element required for the initiation of DNA replication and packaging of recombinant AAV genome into infectious virus particles. .
  • AAV cannot replicate independently in the absence of helper viruses. Therefore, AAV can only be integrated into the host cell chromosome at a specific site and remain in a latent state.
  • the helper virus the increased expression of the rep gene can rescue the AAV genome integrated in the host cell chromosome, and a large amount of AAV DNA is obtained.
  • the single-stranded rAAV genome is packaged into a complex structure under the action of the VP capsid protein. Infectious virus particles.
  • CNE non-protein-coding element
  • NAE sequence was first discovered as an essential element for nucleocapsid assembly in the genus Alphabaculovirus, and it plays an essential role in the nucleocapsid assembly process.
  • the natural NAE sequence is located in the ac83 gene and its homologous genes in the genus Alphabaculovirus, and is located at the near end (CN106566829A).
  • ac83 is a core gene related to baculovirus nucleocapsid assembly. It has a full length of 2544bp, encoding 847 amino acids, and a predicted molecular weight of 96.2kDa. Knocking out ac83 does not affect the replication of the viral genome, but completely blocks the assembly of the viral nucleocapsid. A large number of hollow capsid precursors can be observed in the nucleus under an electron microscope.
  • the invention provides a composition for producing recombinant baculovirus in insect cells, which contains a packaging-deficient baculovirus plasmid and a first rescue recombinant DNA, and the packaging-deficient baculovirus plasmid lacks the baculovirus genome.
  • the packaging-deficient baculovirus plasmid involved in the present invention lacks the CNE sequence and/or the NAE sequence in the baculovirus genome, resulting in the inability to normally package the recombinant baculovirus.
  • the CNE sequence can be exactly the same as the wild-type AcMNPV CNE sequence, or it can be a CNE sequence from other baculoviruses, or it can share at least 50% sequence identity or at least 60% sequence identity with the wild-type AcMNPV CNE sequence.
  • Artificial CNE sequences that are homogeneous, at least 70% sequence identity, at least 80% sequence identity, at least 85% sequence identity, at least 90% sequence identity, at least 95% sequence identity or higher sequence identity.
  • the NAE sequence can be an identical NAE sequence to the wild-type AcMNPV NAE sequence, or it can be an NAE sequence from other baculoviruses, or it can share at least 50% sequence identity, at least 60% sequence identity, and at least 60% sequence identity with the wild-type AcMNPV NAE sequence. % sequence identity, at least 70% sequence identity, at least 80% sequence identity, at least 85% sequence identity, at least 90% sequence identity, at least 95% sequence identity or an artificial NAE sequence of higher sequence identity.
  • the first complement sequence is the CNE sequence
  • the packaging-defective baculovirus plasmid lacks the NAE sequence in the baculovirus genome
  • the first complement sequence is the NAE sequence
  • the packaging-defective baculovirus plasmid simultaneously lacks the CNE sequence and the NAE sequence in the baculovirus genome, correspondingly, the first complement sequence contains both the CNE sequence and the NAE sequence. NAE sequence.
  • the recombinant bacmid after homologous recombination in insect cells contains normal CNE and NAE sequences, and can then package the recombinant baculovirus; but when homologous recombination does not occur, the CNE or NAE sequence is missing on the bacmid. This makes it impossible to package the recombinant baculovirus normally.
  • the second rescue recombinant DNA and the first rescue recombinant DNA can also be used to jointly compensate for the missing sequence, that is, when the packaging-deficient baculovirus plasmid simultaneously deletes the CNE sequence and the NAE sequence in the baculovirus genome
  • the second rescue recombinant DNA includes a second insertion sequence and a second homology arm located on both sides of the second insertion sequence.
  • the second insertion sequence includes a second complement sequence.
  • the first complement sequence is a CNE sequence or an NAE sequence.
  • the second complement sequence is a CNE sequence or a NAE sequence.
  • the complementing sequence is the sequence of the CNE sequence and the NAE sequence that is different from the first complementing sequence.
  • first homology arm and the second homology arm are homologous sequences corresponding to different loci on the baculovirus genome, so that the first insertion sequence and the second insertion sequence can be inserted into the baculovirus genome. in different loci.
  • the rescue recombinant DNA involved in the present invention can be either a linear DNA fragment or a baculovirus transfer vector, which is not limited here.
  • the rescue recombinant DNA provided by the present invention has no restriction on the insertion site.
  • the insertion sequence on the rescue recombinant DNA can be inserted into the baculovirus genome. Any locus, such as, but not limited to, Ac18, Ac83, Ac96, Ac126, Ac127, Ac130, Ac152.
  • the first functional fragment in the present invention can be the cap gene expression cassette of AAV and the rep gene expression cassette of AAV, or it can be the AAV ITR core expression element (i.e. ITR-GOI) with exogenous genes, which is used to prepare recombinant adenocarcinoma.
  • the foreign gene can be at least one nucleotide sequence encoding a gene of interest (Gene of Interest, GOI) product.
  • the gene product of interest can be a therapeutic gene product, specifically a polypeptide, an RNA molecule ( siRNA) or other gene products, such as but not limited to lipoprotein esterase, apolipoprotein, cytokines, interleukins or interferons; it can also be a reporter protein that evaluates vector transformation and expression, such as but not limited to fluorescent protein (green Fluorescent protein (GFP, red fluorescent protein (RFP)), chloramphenicol acetyltransferase, ⁇ -galactosidase, ⁇ -glucuronidase, Renilla luciferase, firefly luciferase or alkaline phosphatase.
  • fluorescent protein green Fluorescent protein (GFP, red fluorescent protein (RFP)
  • chloramphenicol acetyltransferase chloramphenicol acetyltransferase
  • ⁇ -galactosidase ⁇ -glucuronidase
  • the first functional fragment can also be a reporter gene, such as but not limited to expressing fluorescent proteins (green fluorescent protein GFP, red fluorescent protein RFP), chloramphenicol acetyltransferase, ⁇ -galactosidase, ⁇ -glucuronide
  • the gene sequence of the enzyme Renilla luciferase, firefly luciferase or alkaline phosphatase, is used to evaluate and verify whether homologous recombination has occurred to produce recombinant baculovirus.
  • the first functional fragment can also be any nucleotide sequence encoding a therapeutic gene product, such as but not limited to encoding a drug polypeptide (such as interleukin, etc.) or a recombinant viral subunit protein.
  • the specific positions and directions of the cap gene expression cassette and rep gene expression cassette are not limited.
  • the arrangement of the three parts of the cap gene expression cassette, rep gene expression cassette and the first complement sequence can be as follows: Six types: 1. Arranged from the 5' end to the 3' end are the cap gene expression cassette, rep gene expression cassette and the first complement sequence; 2. Arranged from the 5' end to the 3' end are the rep gene expression cassette, cap gene expression cassette and the first complement sequence; 3. Arranged from the 5' end to the 3' end are the cap gene expression cassette, the first complement sequence and the rep gene expression cassette; 4.
  • the rep gene expression cassette, the first complementation sequence and the cap gene expression cassette From the 5' end to the 3' end Arranged in order are the rep gene expression cassette, the first complementation sequence and the cap gene expression cassette; 5. From the 5' end to the 3' end, the first complementation sequence, the cap gene expression cassette and the rep gene expression cassette are arranged in order; 6. Arranged from the 5' end to the 3' end are the first complement sequence, rep gene expression cassette and cap gene expression cassette.
  • the cap gene expression cassette and the rep gene expression cassette can be in the same direction or in opposite directions.
  • the sequence of the cap gene expression cassette in the recombinant expression cassette can be from the 5' end to the 3' end, or from the 3' end to the 5' end.
  • the sequence of the rep gene expression cassette in the recombinant expression cassette can be from the 5' end to the 3' end, or from the 3' end to the 5' end.
  • the first complementation sequence is located between the cap gene expression cassette and the rep gene expression cassette.
  • the first insertion sequence includes the cap gene expression cassette, CNE sequence and rep in order from 5' to 3'.
  • the gene expression cassette, or the first insertion sequence contains the cap gene expression cassette, the NAE sequence and the rep gene expression cassette in the order from 5' to 3', or the first insertion sequence contains the rep gene expression in the order from 5' to 3' cassette, CNE sequence and cap gene expression cassette, or comprise rep gene expression cassette, NAE sequence and cap gene expression cassette in order from 5' to 3'.
  • the two ends of the first complementation sequence are respectively close to the starting end of the cap gene expression cassette and the starting end of the rep gene expression cassette, that is, the cap gene expression cassette and the rep gene expression cassette are in opposite directions, and the starting ends of the two are respectively. Set oppositely and towards the first backfill sequence.
  • An insect cell provided by the invention includes any of the above compositions.
  • the invention provides a method for growing or producing recombinant baculovirus in vitro, which method includes co-transfecting insect cells with any of the above compositions and cultivating the insect cells. The recombinant baculovirus can then be recovered.
  • the present invention also provides a method for growing or producing recombinant adeno-associated viruses in vitro, which method includes co-transfecting insect cells with the above composition, and cultivating the insect cells to produce recombinant adeno-associated viruses.
  • the composition required to prepare the recombinant adeno-associated virus needs to contain the AAV cap gene, rep gene and ITR core expression element necessary for the production of rAAV. Therefore, if the first rescue recombinant DNA in the composition contains AAV's cap gene, rep gene and ITR core expression element, cap gene expression cassette and AAV rep gene expression cassette, you also need to insert the AAV ITR core expression element with foreign genes into the packaging-deficient baculovirus plasmid.
  • the first rescue recombinant DNA in the composition contains the AAV ITR core expression element with foreign genes, it is also necessary to insert the AAV cap gene expression cassette and the AAV rep gene expression cassette into the packaging-defective baculovirus plasmid. Can be obtained by baculovirus transfer vector-mediated Tn7 transposition.
  • the purpose of obtaining rAAV can also be achieved through two rescue recombinant DNAs.
  • the packaging-deficient baculovirus plasmid simultaneously deletes the CNE sequence and NAE sequence in the baculovirus genome.
  • the first rescue recombinant DNA contains the expression of the cap gene of AAV. cassette, AAV rep gene expression cassette and CNE sequence, and the second rescue recombinant DNA contains the AAV ITR core expression element and NAE sequence with foreign genes.
  • Example 1 Construction of bacmids lacking CNE sequence ⁇ CNE-Bac, bacmids lacking NAE sequences ⁇ NAE-Bac, and bacmids ⁇ CNE- ⁇ NAE-Bac lacking both CNE and NAE sequences
  • Red recombination is a highly efficient recombination method at the bacterial level that can be used to rapidly transform recombinant baculovirus genomes in Escherichia coli (DH10Bac).
  • Red recombination uses lambda phage Red recombinase (composed of three proteins: Exo, Beta and Gam) to perform homologous recombination between linear DNA fragments carrying homology arms introduced into cells and specific target sequences of the genome, thereby achieving the target gene. Replacement (Doublet et al., 2008, J Microbiol Methods, 75(2): 359-361).
  • the first homologous recombination expression cassette (SEQ ID No. 1) targeting the CNE sequence is constructed.
  • the expression cassette includes the CNE upstream homologous sequence and chloramphenicol (Chol) from 5' to 3'. Resistance gene expression cassette and CNE downstream homologous sequence; then Red recombination technology was used to replace the expression cassette with the CNE sequence on the bacmid, thereby obtaining a bacmid ⁇ CNE-Bac lacking the CNE sequence.
  • the expression cassette includes the NAE upstream homologous sequence, chloramphenicol, and (Chol) resistance gene expression cassette and NAE downstream homologous sequence; then Red recombination technology was used to replace the expression cassette with the NAE sequence on the bacmid, thereby obtaining a bacmid ⁇ NAE-Bac lacking the NAE sequence.
  • the third homologous recombination expression cassette (SEQ ID No. 3) targeting the NAE sequence is first constructed, as shown in Figure 3.
  • the expression cassette includes the NAE upstream homologous sequence, Gentamella sp. Gene (GM) resistance gene expression cassette and NAE downstream homologous sequence; then Red recombination technology was used to replace the expression cassette with the NAE sequence on the bacmid ⁇ CNE-Bac, thus obtaining a gene lacking both CNE and NAE sequences.
  • green fluorescent protein (GFP) or red fluorescent protein (mcherry) is used as an exogenous gene to be inserted into the AcMNPV genome.
  • the recombinant DNA fragment includes the orf96 upstream homologous sequence and the CNE sequence (SEQ ID No. 4) from 5' to 3'.
  • GFP expression cassette and orf96 downstream homologous sequence the above sequences were connected through artificial direct synthesis or overlap extension PCR amplification to obtain the construct Ac96-CNE-GFP respectively.
  • the construct Ac96-NAE-mcherry containing the NAE sequence was constructed ( Figure 5).
  • the nucleotide sequences of construct Ac96-CNE-GFP and construct Ac96-NAE-mcherry are shown in SEQ ID No. 6 and SEQ ID No. 7 respectively.
  • This recombinant DNA fragment includes the orf96 upstream homologous sequence and the Rep gene expression cassette from 5' to 3'. (SEQ ID No.8), CNE sequence, Cap gene expression cassette (SEQ ID No.9) and orf96 downstream homologous sequence, the above sequences are connected through artificial direct synthesis or overlap extension PCR amplification to obtain the construct Ac96- Rep-CNE-Cap. Similarly, the construct Ac96-Rep-NAE-Cap containing the NAE sequence was constructed (Fig. 7). The nucleotide sequences of construct Ac96-Rep-CNE-Cap and construct Ac96-Rep-NAE-Cap are shown in SEQ ID No. 10 and SEQ ID No. 11 respectively.
  • Example 3 Verification of homologous recombination to produce recombinant baculovirus after co-transfection of packaging-deficient baculovirus vector and recombinant DNA fragment into insect host cells
  • the packaging-deficient baculovirus vectors ⁇ CNE-Bac and ⁇ NAE-Bac constructed in Example 1 were co-constructed with the corresponding recombinant DNA fragments Ac96-CNE-GFP and Ac96-NAE-mcherry constructed in Example 2, respectively.
  • 120 h after co-transfection the Sf9 cell culture supernatant was collected and transferred to the host cells cultured in suspension. After 72 h of infection, green fluorescence or red fluorescence was observed with a fluorescence microscope. Luminous condition.
  • Example 4 Foreign genes can be inserted into any locus of the AcMNPV genome. There is no restriction on the insertion site and can be inserted into the target site as needed.
  • Example 2 construct recombinant DNA fragments with insertion sites at orf83, orf126 and orf152 respectively, as shown in Figures 12A-F:
  • the constructs Ac83-CNE-GFP ( Figure 12A) and Ac126-CNE-GFP ( Figure 12B ) and Ac152-CNE-GFP (( Figure 12C) are recombinant DNA fragments with CNE complement sequence insertion sites at orf83, orf126 and orf152 respectively
  • the constructs Ac83-NAE-mcherry ( Figure 12D), Ac126-NAE -mcherry ( Figure 12E) and Ac152-NAE-mcherry ( Figure 12F) are recombinant DNA fragments with NAE complement sequence insertion sites at orf83, orf126 and orf152 respectively;
  • the packaging-deficient baculovirus vectors ⁇ CNE-Bac and ⁇ NAE-Bac in Example 1 were co-transfected into Sf9 insect host cells with the recombinant DNA fragment in this example. After co-transfection for 96 hours, using Use a fluorescence microscope to observe whether the host cells can produce green fluorescent plaques or red fluorescent plaques to determine the production of recombinant baculovirus. In order to further confirm that co-transfection indeed produced recombinant baculovirus, 120 h after co-transfection, the Sf9 cell culture supernatant was collected and transferred to the host cells cultured in suspension. After 72 h of infection, green fluorescence or red fluorescence was observed with a fluorescence microscope. Luminous condition.
  • Example 5 Obtaining recombinant baculovirus containing Cap and Rep, essential elements for AAV packaging, and detecting the expression of Cap and Rep
  • the packaging-deficient baculovirus vector ⁇ CNE-Bac in Example 1 and the recombinant DNA fragment Ac96-Rep-CNE-Cap in Example 2 were co-transfected into Sf9 insect cells, and the packaging-deficient rod in Example 1
  • the ravivirus vector ⁇ NAE-Bac and the recombinant DNA fragment Ac96-Rep-NAE-Cap in Example 2 were co-transfected into Sf9 insect cells to prepare recombinant baculovirus BEV.
  • the transfected Sf9 insect cells successfully produced BEV, and further infection with a large number of replicating and proliferating BEV caused obvious cytopathic effect (CPE) in Sf9 cells.
  • CPE cytopathic effect
  • the culture supernatant of Sf9 cells that developed CPE was collected, which contains a large amount of BEV, which is the 0th generation BEV (BEV-P0).
  • BEV-P0 the 0th generation BEV
  • the cell culture medium was centrifuged at 1000g for 5 minutes, and the culture supernatant and cell pellet were collected respectively. The supernatant was labeled as passage 1 BEV (BEV-P1).
  • Example 1 in the applicant's previous patent application CN112553257A, which includes the following steps:
  • ITR-GOI a recombinant transfer vector containing the ITR core element
  • the nucleotide sequence of ITR-GOI is shown in SEQ ID No. 12.
  • the GOI in the ITR core element uses the red fluorescent protein mcherry gene expression cassette, that is, the miniEf1a promoter controls mcherry expression, which facilitates the detection of rAAV activity.
  • the ITR and red fluorescent protein expression cassettes are constructed into the transfer vector pFastDual.
  • step (2) Use the recombinant transfer vector constructed in step (1) above to transform competent cells containing ⁇ CNE-Bac or ⁇ NAE-Bac bacmid, and use Tn7 recombination to insert ITR-GOI into ⁇ CNE-Bac or ⁇ NAE- On the Tn7 site of the Bac bacmid, recombinant baculovirus plasmids containing the ITR core elements necessary for rAAV production were finally obtained, numbered ⁇ CNE-Bac-Tn7-ITR and ⁇ NAE-Bac-Tn7-ITR respectively.
  • Example 7 Using ⁇ CNE-Bac-Tn7-ITR or ⁇ NAE-Bac-Tn7-ITR deficient bacmid to prepare AAV recombinant baculovirus containing the essential elements Cap, Rep and ITR-GOI for AAV packaging
  • Example 6 The recombinant bacmid ⁇ CNE-Bac-Tn7-ITR prepared in Example 6 was combined with the recombinant DNA fragment Ac97-Rep-CNE-Cap prepared in Example 2, and the recombinant bacmid ⁇ NAE-Bac prepared in Example 6 -Tn7-ITR and the recombinant DNA fragment Ac97-Rep-NAE-Cap prepared in Example 2 were co-transfected into the host insect cell line and cultured to obtain AAV recombinant baculovirus, numbered respectively ⁇ CNE-Bac-AAV and ⁇ NAE- Bac-AAV, the specific steps are as follows:
  • the above recombinant bacmid and transfer vector DNA were extracted and co-transfected into Sf9 insect cells to prepare recombinant baculovirus BEV and rAAV.
  • the co-transfected Sf9 insect cells successfully produced BEV, and further infection with a large number of replicated and proliferated BEV caused obvious cytopathic effects (CPE) in Sf9 cells.
  • CPE cytopathic effects
  • the culture supernatant of Sf9 cells that developed CPE was collected, which contains a large amount of BEV, which is the 0th generation BEV (BEV-P0).
  • BEV-P0 0th generation BEV
  • the cell culture medium was centrifuged at 1000g for 5 minutes, and the culture supernatant and cell pellet were collected respectively.
  • the supernatant was labeled with passage 1 BEV (BEV-P1), and the cells were labeled with rAAV packaged with BEV-P0.
  • Example 8 Preparation of AAV recombinant baculovirus containing the essential elements Cap, Rep and ITR-GOI for AAV packaging using ⁇ CNE- ⁇ NAE-Bac deficient bacmid
  • a recombinant DNA fragment with the insertion site of the AAV ITR core expression element (ITR-GOI) at the AcMNPV orf83 locus was constructed: see Figure 19.
  • the recombinant DNA fragment includes orf83 upstream homologous sequence, ITR- GOI sequence, NAE sequence and orf83 downstream homologous sequence, the above sequences are connected through artificial direct synthesis or overlap extension PCR amplification to obtain the construct Ac83-ITR-NAE.
  • Example 1 the defective bacmid ⁇ CNE- ⁇ NAE-Bac prepared in Example 1 was combined with the recombinant DNA fragment Ac97-Rep-CNE-Cap prepared in Example 2, and the recombinant DNA fragment Ac83-ITR prepared in this example.
  • -NAE was co-transfected into the host insect cell line and cultured to obtain an AAV recombinant baculovirus, numbered ⁇ CNE- ⁇ NAE-Bac-AAV. Please refer to Example 7 for specific steps.
  • Example 9 Purification of recombinant AAV virus particles and detection of packaging efficiency
  • Example 5 the recombinant baculovirus ⁇ CNE-Bac-AAV, ⁇ NAE-Bac-AAV and ⁇ CNE- ⁇ NAE-Bac-AAV in Example 7 and Example 8 are continued to be expanded and cultured until BEV is used.
  • Lane 1 is the silver staining detection picture of the purified recombinant AAV virus particles subjected to SDS-PAGE after the recombinant baculovirus ⁇ CNE-Bac-AAV infected the host cells, showing three Capsid proteins VP1/VP2/VP3;
  • lane 2 is the silver staining detection picture of the purified recombinant AAV virions subjected to SDS-PAGE after the recombinant baculovirus ⁇ NAE-Bac-AAV infected the host cells, showing the three capsids.
  • Protein VP1/VP2/VP3 Lane 3 is the silver staining detection picture of SDS-PAGE of purified recombinant AAV virions after infecting host cells with recombinant baculovirus ⁇ CNE- ⁇ NAE-Bac-AAV, showing three types of capsids. Proteins VP1/VP2/VP3.
  • This embodiment also uses Q-PCR to detect the packaging rate of the harvested rAAV virus.
  • the detection of the rAAV packaging rate uses a pair of primers targeting the ITR sequence (Q-ITR-F: GGAACCCTAGTGATGGAGTT and Q-ITR-R: CGGCCTCAGTGAGCGA). The test results are shown in Table 1.
  • This example shows that the defective baculovirus vector and recombinant DNA fragment provided by the present invention can be directly recombined in insect host cells to prepare AAV recombinant baculovirus containing the essential AAV packaging elements Cap, Rep and ITR-GOI. and successfully produced AAV virions.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne une composition et un procédé pour générer un baculovirus recombiné dans une cellule d'insecte, et son utilisation. La composition comprend un plasmide de baculovirus présentant une déficience d'encapsulation et un premier ADN recombiné de sauvetage. Le plasmide de baculovirus présentant une déficience d'encapsulation est dépourvu d'une séquence CNE et/ou d'une séquence NAE dans un génome de baculovirus ; le premier ADN recombiné de sauvetage comprend une première séquence d'insertion et des premiers bras homologues situés de part et d'autre de la première séquence d'insertion ; la première séquence d'insertion comprend un premier fragment fonctionnel et une première séquence de complément ; la première séquence de complément est au moins l'une des séquences supprimées du plasmide de baculovirus présentant une déficience d'encapsulation ; et la composition peut subir une recombinaison homologue dans la cellule d'insecte pour produire un baculovirus recombiné. Le baculovirus recombiné peut être obtenu par recombinaison en une étape de la composition dans une cellule d'insecte hôte sans criblage et sans restriction d'un seul site de recombinaison, afin que la pureté du baculovirus recombiné préparé soit relativement élevée.
PCT/CN2022/101538 2022-05-16 2022-06-27 Composition et procédé pour générer un baculovirus recombiné dans une cellule d'insecte, et utilisation WO2023221240A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210529014.7 2022-05-16
CN202210529014.7A CN114736929B (zh) 2022-05-16 2022-05-16 一种用于昆虫细胞中产生重组杆状病毒的组合物、方法及应用

Publications (1)

Publication Number Publication Date
WO2023221240A1 true WO2023221240A1 (fr) 2023-11-23

Family

ID=82286346

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/101538 WO2023221240A1 (fr) 2022-05-16 2022-06-27 Composition et procédé pour générer un baculovirus recombiné dans une cellule d'insecte, et utilisation

Country Status (2)

Country Link
CN (1) CN114736929B (fr)
WO (1) WO2023221240A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101100680A (zh) * 2007-06-15 2008-01-09 中国科学院武汉病毒研究所 高效表达sars冠状病毒s蛋白的重组杆状病毒及构建
CN102007209A (zh) * 2008-02-19 2011-04-06 阿姆斯特丹分子治疗(Amt)股份有限公司 细小病毒rep和cap蛋白在昆虫细胞中的表达优化
CN106566829A (zh) * 2016-11-01 2017-04-19 中山大学 一种核衣壳装配必需元件及其应用
CN108699567A (zh) * 2016-04-21 2018-10-23 威洛克有限公司 昆虫细胞中的aav产生、其方法和组合物
CN109609552A (zh) * 2018-12-28 2019-04-12 中国科学院武汉物理与数学研究所 重组腺相关病毒的制备方法、系统及重组杆粒

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9919409D0 (en) * 1999-08-18 1999-10-20 Univ Oxford Brookes Baculovirus expression system
GB0012997D0 (en) * 2000-05-26 2000-07-19 Eurogene Limited Gene delivery
CN103484499A (zh) * 2013-09-27 2014-01-01 浙江理工大学 复制缺陷型BmNPV载体的构建及应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101100680A (zh) * 2007-06-15 2008-01-09 中国科学院武汉病毒研究所 高效表达sars冠状病毒s蛋白的重组杆状病毒及构建
CN102007209A (zh) * 2008-02-19 2011-04-06 阿姆斯特丹分子治疗(Amt)股份有限公司 细小病毒rep和cap蛋白在昆虫细胞中的表达优化
CN108699567A (zh) * 2016-04-21 2018-10-23 威洛克有限公司 昆虫细胞中的aav产生、其方法和组合物
CN106566829A (zh) * 2016-11-01 2017-04-19 中山大学 一种核衣壳装配必需元件及其应用
CN109609552A (zh) * 2018-12-28 2019-04-12 中国科学院武汉物理与数学研究所 重组腺相关病毒的制备方法、系统及重组杆粒

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HUANG ZHIHONG, MENGJIA PAN, SILEI ZHU, HAO ZHANG, WENBI WU, MEIJIN YUAN, KAI YANG: "The Autographa californica Multiple Nucleopolyhedrovirus ac83 Gene Contains a cis-Acting Element That Is Essential for Nucleocapsid Assembly", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 91, no. 5, 1 March 2017 (2017-03-01), US , pages e02110 - 16, XP093109264, ISSN: 0022-538X, DOI: 10.1128/JVI.02115-16 *
HUANG, ZHIHONG ET AL.: "The Autographa californica Multiple Nucleopolyhedrovirus ac83 Gene Contains a cis-Acting Element That Is Essential for Nucleocapsid Assembly", JOURNAL OF VIROLOGY, vol. 91, no. 5, 14 February 2017 (2017-02-14), XP093109264, ISSN: 0022-538X, DOI: 10.1128/JVI.02115-16 *
IRINA KIKHNO ET AL.: "Identification of a conserved non-protein-coding genomic element that plays an essential role in Alphabaculovirus pathogenesis", PLOS ONE, vol. 9, no. 4, 16 April 2014 (2014-04-16), XP093109263, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0095322 *

Also Published As

Publication number Publication date
CN114736929B (zh) 2023-06-09
CN114736929A (zh) 2022-07-12

Similar Documents

Publication Publication Date Title
AU706647B2 (en) Process for preparing recombinant adeno-associated viruses (AAVs), and uses
CA2359748A1 (fr) Procede de fabrication d'un virus adeno-associe recombine, moyens adaptes a cette fabrication et utilisation dudit virus pour la fabrication d'un medicament
US20040087026A1 (en) Host cells for packing a recombinant adeno-associated virus (raav), method for the production and use thereof
US20020051769A1 (en) Gene delivery vectors and their uses
CN109609552B (zh) 重组腺相关病毒的制备方法、系统及重组杆粒
WO2023039936A1 (fr) Cassette d'expression pour exprimer un gène contenant un cadre de lecture ouvert se chevauchant dans une cellule d'insecte, et son utilisation
AU2021217799A1 (en) Process for making adenoassociated viral vectors
Wu et al. Development of versatile and flexible Sf9 packaging cell line-dependent OneBac system for large-scale recombinant adeno-associated virus production
WO2023092643A1 (fr) Cassette d'expression d'un gène contenant un cadre de lecture ouvert chevauchant et application de la cassette d'expression dans des cellules d'insectes
JP2023511288A (ja) 組換えアデノ随伴ウイルスの作製方法、システム及び組換えバクミド
WO2024067153A1 (fr) Acide nucléique pour la production de raav dans une cellule d'insecte, mutant de protéine de capside vp1 et utilisation
CN109207520B (zh) Leber遗传性视神经病变的基因药物
US11708585B2 (en) Method, system and recombinant bacmid for preparation of recombinant adeno-associated virus
Xiao et al. Adeno-associated virus (AAV) vectors for gene transfer
WO2023221240A1 (fr) Composition et procédé pour générer un baculovirus recombiné dans une cellule d'insecte, et utilisation
WO2005035743A1 (fr) Procede de production, d'isolation, de purification et utilisations de vecteurs virus adeno-associes recombinants multi-types
WO2023221241A1 (fr) Vecteur de baculovirus et son utilisation pour la préparation de raav dans une cellule d'insecte
CN117165629A (zh) 一种用于在酵母细胞中获得重组杆状病毒载体的组合物及应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22942271

Country of ref document: EP

Kind code of ref document: A1